Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins was written by Sun, Weilin;Netzer, William J.;Sinha, Anjana;Gindinova, Katherina;Chang, Emily;Sinha, Subhash C.. And the article was included in Journal of Medicinal Chemistry in 2019.SDS of cas: 162046-66-4 This article mentions the following:
Imatinib mesylate, I, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein (APP) and mediates a synergistic effect, when combined with a β-secretase inhibitor, BACE IV. Toward developing more potent brain-permeable leads, we have synthesized and evaluated over 75 I-analogs. Several compounds inhibited production of Aβ peptides with improved activity in cells. These compounds affected β-secretase cleavage of APP similarly to I. Compound II significantly reduced production of the Aβ42 peptide, when administered (100 mg/kg, twice daily by oral gavage) to 5 mo old female mice for 5 days. A combination of compound II with BACE IV also reduced Aβ levels in cells, more than the additive effect of the two compounds These results open a new avenue for developing treatments for Alzheimer’s disease using I-analogs. In the experiment, the researchers used many compounds, for example, 4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)benzoic acid (cas: 162046-66-4SDS of cas: 162046-66-4).
4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)benzoic acid (cas: 162046-66-4) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 °C and boils at 125–130 °C. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.SDS of cas: 162046-66-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics